refurb is right - we essentially do this now, our limitations are: - Cost of sequencing - Toxicity of current drugs in combination - lack of suitable drugs

refurb is right - we essentially do this now, our limitations are: - Cost of sequencing - Toxicity of current drugs in combination - lack of suitable drugs - lack of patient trials More on the last: This is on which everything depends. Medical ethics 'bends' a lot of allowances with regard to anti-cancer drugs because of the stakes but you can't just start introducing things willy-nilly. A new drug does not a cure make. And drugs have interactions, sometimes serious. Using one new drug may lead to some shift of the survival curve (or at least shrinkage of tumour, maybe it is now more susceptible to Surgery/Radiation or is just going to give them better quality of life) but adding additional drugs may reverse this trend if they are not properly researched All this requires money All this takes years But a surprising amount is already in progress. Sitting in on case conferences with practicing Oncologists and Radiologists, they have combinations of drugs with strange names 'R-CHOP' etc - have a wiki - to roll out against standards, are always reciting the latest literature, trying to get patients into new trials that show promise, all in the hope of continually shifting the survival curve further to the right